共 32 条
[1]
Long W., Thompson T., Sundell H., Et al., Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome, J Pediatr, 118, pp. 595-605, (1991)
[2]
Long W., Cofbet A., Cotton R., Et al., A controlled trial of synthetic surfactant in infants weighing 1,250 grams or more with respirutory distress syndrome, N Engl J Med, 325, (1991)
[3]
Combet A., Bucciarelli R., Gotdlrnln S., Et al., Decreased monality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial, J Pcdiatr, 118, (1991)
[4]
Kitzhabcr J., The Oregon Health Plan, (1992)
[5]
Guidelines for preparation of economic analyses tObe included in submision to drug programs branch for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index, (1991)
[6]
Detsky A.S., Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics, 3, (1993)
[7]
Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, including submissions involving economic analyses, (1992)
[8]
Drummond M., Smith G.T., Wells N., Economic evaluation in the development of medicines, London: Office of Health Economics, (1988)
[9]
Backhouse M., Backhause R., Edey S., Economic evaluation bibliography, Health Econ, 1, pp. 1-236, (1992)
[10]
Pancth N., Kiely J.L., Wallenstein S., Et al., Newborn intensive care and neonatal mortality in low-birth weight in fants: a population study, N Engl J Med, 307, (1982)